Continuous infusion vancomycin for treatment of methicillin-resistant staphylococcus aureus in cystic fibrosis patients

Annals of Pharmacotherapy

Volumn 46, Issue 10, 2012, Pages

  Fung, Lela ^a  

^a Neona tology/Pediatrics   (United States)

Author keywords

Continuous infusion; Cystic fibrosis; MRSA; Staphylococcus aureus; Vancomycin

Indexed keywords

COLISTIMETHATE; CREATININE; DOXAZOSIN; LEVOFLOXACIN; LINEZOLID; MEROPENEM; SALBUTAMOL; VANCOMYCIN;

ADOLESCENT; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; CASE REPORT; CENTRAL VENOUS CATHETER; CHILD; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; CYSTIC FIBROSIS; DISEASE EXACERBATION; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG SAFETY; FEMALE; FEVER; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; KIDNEY CLEARANCE; LUNG FUNCTION TEST; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; NEPHROLITHIASIS; OUTPATIENT CARE; OXYGEN SATURATION; PRESCHOOL CHILD; PRESCRIPTION; PRIORITY JOURNAL; SPUTUM CULTURE; TREATMENT DURATION; UREA BLOOD LEVEL; URINE VOLUME;

ADOLESCENT; ANTI-BACTERIAL AGENTS; CHILD, PRESCHOOL; CYSTIC FIBROSIS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCAL INFECTIONS; VANCOMYCIN;

EID: 84867770396     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1R272     Document Type: Article

References (13)

1. de Vrankrijker AMM, Wolfs TFW, van der Ent CK. Challenging and emerging pathogens in cystic fibrosis. Paediatr Resp Rev 2010;11:246-54.
2. Touw DJ. Clinical pharmacokinetics of antimicrobial drugs in cystic fi-brosis. Pharm World Sci 1998;20:149-60.
3. Pleasants RA, Michalets EL, Williams DM, et al. Pharmacokinetics of vancomycin in adult cystic fibrosis patients. Antimicrob Agents Chemother 1996;40:186-90.
4. Rybak M, Lomaestro B, Rotschafer J, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Soci-ety of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009;66:82-98.
5. Wysocki M, Delatour F, Faurisson F, et al. Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: prospective multicenter randomized study. Antimicrob Agents Chemother 2001;45: 2460-7.
6. Denis O, Nonhoff C, Baudouin B, et al. Emergence of vancomycin-inter-mediate Staphylococcus aureus in a Belgian hospital: microbiological and clinical features. J Antimicrob Chemother 2002;50:383-91.
7. Bauer LA. Pharmacokinetic equations and calculations. In: Clinical phar-macokinetics handbook. New York: McGraw-Hill Medical Pubications, 2006:19-52.
8. DeRyke CA, Alexander DP. Optimizing vancomycin dosing through phar-macodynamic assessment targeting area under the concentration-time curve/minimum inhibitory concentration. Hosp Pharm 2009;44:751-65.
9. Moise-Broder PA, Forrest A, Birmingham MC, et al. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus au-reuslower respiratory tract infections. Clin Pharmacokinet 2004;43:925-42.
10. Chua K, Howden BP. Treating gram-positive infections: vancomycin up-date and the whys, wherefores and evidence base for continuous infusion of anti-gram-positive antibiotics. Curr Opin Infect Dis 2009;22:525-34.
11. Spapen HD, Janssen van Doorn K, Diltoer M, et al. Retrospective evalu-ation of possible renal toxicity associated with continuous infusion of vancomycin in critically ill patients. Ann Intensive Care 2011;1:26.
12. Cataldo MA, Tacconelli E, Grilli E, et al. Continuous versus intermittent in-fusion of vancomycin for the treatment of gram-positive infections: system-atic review and meta-analysis. J Antimicrob Chemother 2012;67:17-24.
13. Ingram PR, Lye DC, Tambyah PA, et al. Risk factors for nephrotoxicity associated with continuous vancomycin infusion in outpatient parenteral antibiotic therapy. J Antimicrob Chemother 2008;62:168-71.